While the benefits of treatment with bevacizumab are well studied in American and European patients with stage IV CRC, the effect and safety of treatment with bevacizumab combined chemotherapy in Chinese patients, and whether the KRAS mutation status and primary tumor site could affect the prognosis of Chinese stage IV CRC have not been demonstrated clearly. The gene discussed is KRAS; the disease is neoplasm.